logo
logo

YolTech raises $45M for its first Phase 3 study.

Sep 10, 2025•17 days ago

Amount Raised

$45 Million

ShanghaiBiotechnology

Description

YolTech, a Chinese CRISPR company, has successfully raised $45 million. The funds will be utilized to initiate its first Phase 3 study. This funding round demonstrates confidence in YolTech's innovative approach. The investment is crucial as it aims to accelerate their research and development efforts.

Company Information

Company

YolTech

Location

Shanghai, Shanghai, China

About

YolTech is a Chinese company specializing in CRISPR technology. The company aims to innovate and develop advanced solutions in gene editing. They are preparing for their first Phase 3 clinical study, indicating substantial progress in their research. YolTech is focused on transforming biotechnology applications in medicine.

Related People

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech